Welcome to our dedicated page for Mallinckrodt plc news (Ticker: MNKTQ), a resource for investors and traders seeking the latest updates and insights on Mallinckrodt plc stock.
Mallinckrodt plc (MNKTQ) is a global leader in specialty pharmaceuticals and medical imaging, with focused research in autoimmune disorders and critical care therapies. This news hub provides investors and healthcare professionals with timely updates on regulatory developments, clinical research advancements, and strategic initiatives across neurology, rheumatology, and rare disease treatments.
Our curated news collection offers essential insights into MNKTQ's product pipeline updates, FDA filings, partnership announcements, and financial performance reports. Stay informed about developments in Mallinckrodt's core therapeutic areas including nephrology, ophthalmology solutions, and contrast imaging technologies.
Key updates include regulatory submissions, clinical trial milestones, manufacturing expansions, and peer-reviewed research publications. Bookmark this page for direct access to primary source materials and official statements from Mallinckrodt leadership.
Rhea-AI Summary
Mallinckrodt plc announced the addition of four seasoned professionals to its Board of Directors, including Paul Bisaro as Board Chair. Siggi Olafsson will continue as President, CEO, and Board Member. The company aims to strengthen its leadership team and continue to deliver for its patients and public health needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Mallinckrodt plc announced the presentation of findings from a post hoc analysis of the Phase 3 CONFIRM clinical trial, showing the therapeutic effect of TERLIVAZ in adult patients with hepatorenal syndrome and alcoholic hepatitis. The analysis found that the incidence of verified HRS reversal was significantly higher in patients treated with TERLIVAZ vs. placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Mallinckrodt plc (MNK) emerges from Chapter 11 with a strengthened balance sheet and increased financial flexibility. Recent progress includes net sales and adjusted EBITDA growth, FDA acceptance of Acthar® Gel delivery device, positive momentum for Terlivaz®, and growth for Therakos®. The Specialty Generics segment benefits from vertical integration and U.S.-based manufacturing plants, with three FDA abbreviated new drug application approvals. The company reduced its total funded debt by approximately $1.9 billion and satisfied obligations to the Opioid Master Disbursement Trust II.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-100%
Tags
Rhea-AI Summary
Mallinckrodt plc (OTCMKTS: MNKTQ) announced 11 scientific abstracts at the AASLD 2023 Liver Meeting, presenting findings from clinical and health economics research with TERLIVAZ (terlipressin) for injection for adult patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function. The research details the clinical efficacy, safety, and real-world utility of TERLIVAZ, the first and only FDA-approved product to improve kidney function in adults with HRS with rapid reduction in kidney function.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
-
Rhea-AI Summary
Mallinckrodt plc reported a 6.8% increase in net sales for the third quarter of 2023, reaching $497.0 million. The company's financial restructuring plan was approved by the U.S. Bankruptcy Court, positioning it to complete the Irish Examinership and emerge from Chapter 11 in the near term. The company's Specialty Generics segment experienced a 30.2% increase in net sales, while the Specialty Brands segment reported a 5.7% decrease. Adjusted EBITDA for the third quarter was $180.6 million, an 8.7% increase compared to the prior year quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
-
Rhea-AI Summary
Mallinckrodt plc announced that three scientific abstracts evaluating treatment with TERLIVAZ for adults with hepatorenal syndrome (HRS) will be presented at the American Society of Nephrology Kidney Week 2023 Scientific Meeting. TERLIVAZ is the first FDA-approved product indicated to improve kidney function in adults with HRS. The abstracts will explore the impact of TERLIVAZ on patient care, key HRS endpoints, patient comorbidity, and the role of TERLIVAZ in HRS reversal. The studies are sponsored by Mallinckrodt Pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.54%
Tags
Rhea-AI Summary
Mallinckrodt plc shared findings from health economics research on Acthar Gel for patients with advanced symptomatic sarcoidosis and nephrotic syndrome. The cost-effectiveness analysis showed that Acthar Gel resulted in an incremental cost-effectiveness ratio (ICER) of $134,796 per quality-adjusted life-year (QALY) and $39,179 per QALY over two and three years, respectively. From a societal perspective, Acthar versus standard of care resulted in an ICER of $117,622 per QALY over two years and $21,967 per QALY over three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
-
Rhea-AI Summary
Mallinckrodt presents findings from clinical studies and health economic analysis of TERLIVAZ for hepatorenal syndrome treatment outcomes at ACG Annual Scientific Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
Mallinckrodt's Plan of Reorganization confirmed by U.S. Bankruptcy Court, positioning the Company to emerge from Chapter 11 by year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.79%
Tags
Rhea-AI Summary
Mallinckrodt publishes two journal manuscripts supporting Acthar Gel's efficacy and economic benefits in autoimmune and inflammatory diseases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.79%
Tags
Mallinckrodt plc
NYSE:MNKTQ
MNKTQ Rankings
MNKTQ Stock Data
1.60M
5.99M
10.09%
96.64%
13.46%
Drug Manufacturers - Specialty & Generic
Healthcare
Ireland
Dublin